Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.
Published: International journal of obesity and related metabolic disorders
Date:
Authors: P A Velasquez-Mieyer 1 , P A Cowan, K L Arheart, C K Buffington, K A Spencer, B E Connelly, G W Cowan, R H Lustig
Abstract:
Hyperinsulinemia is a common feature of many obesity syndromes. We investigated whether suppression of insulin secretion, without dietary or exercise intervention, could promote weight loss and alter food intake and preference in obese adults.
Published: The Journal of Pediatrics
Date:
Authors: R H Lustig 1 , S R Rose, G A Burghen, P Velasquez-Mieyer, D C Broome, K Smith, H Li, M M Hudson, R L Heideman, L E Kun
Abstract:
Hypothalamic obesity is a rare sequela of cranial insult, for which pathogenesis and treatment remain obscure. In rodents ventromedial hypothalamic damage causes hyperphagia, obesity, hyperinsulinism, and insulin resistance. Reduction of insulin secretion in humans may attenuate weight gain.